Stocks and Investing
Stocks and Investing
Wed, March 6, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Sumant Kulkarni Maintained (CARA) at Strong Buy with Decreased Target to $10 on, Mar 6th, 2024
Sumant Kulkarni of Canaccord Genuity, Maintained "Cara Therapeutics, Inc." (CARA) at Strong Buy with Decreased Target from $11 to $10 on, Mar 6th, 2024.
Sumant has made no other calls on CARA in the last 4 months.
There are 3 other peers that have a rating on CARA. Out of the 3 peers that are also analyzing CARA, 1 agrees with Sumant's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Amsellem of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $1 on, Tuesday, November 14th, 2023
These are the ratings of the 2 analyists that currently disagree with Sumant
- Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $5 on, Tuesday, March 5th, 2024
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $2.5 on, Tuesday, December 19th, 2023
Contributing Sources